
Experimental Drug Blocks COVID-19 Viral Entry Into Lung Cells

An experimental compound prevents the virus that causes coronavirus disease 2019 (COVID-19) from entering human airway cells, a new study finds.
An experimental compound prevents the virus that causes coronavirus disease 2019 (COVID-19) from entering human airway cells, a new study finds.
For this reason, molecular biologists have sought to engineer forms of ACE2 that, instead of being woven onto the cell surface, float freely. They hoped that free-floating ACE2 could serve as a decoy that competes with the membrane-bound counterpart for the viral spike protein, thereby blocking virus entry.
Led by researchers at NYU Grossman School of Medicine, a new investigative effort made key changes to a free ACE2 molecule, and then fused one part of it to a piece of an antibody, an immune system protein, with the goal of strengthening its antiviral effect. The team calls their molecule an “ACE-2 microbody.”
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.